SIGRID THERAPEUTICS

Live / Applied — Second extension granted (statement of use) (as of 14 Jan 2026)

What this means for you

Not registered yet, but its 19 Jan 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
98365730
Mark type
Stylized text
Filed
19 Jan 2024
Published for opposition
03 Dec 2024
Attorney of record
Bradley L. Cohn

Goods and services

  • Class 005 — Pharmaceuticals: Nutritional supplements; dietary supplements; dietary and nutritional supplements for the treatment and prevention of obesity and being overweight; dietary and nutritional supplements for boosting daily energy levels, balancing blood sugar, and maintaining healthy weight; dietary and nutritional supplements for the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol, LDL cholesterol levels and blood lipids; dietetic foods adapted for medical purposes; dietetic foods and beverages adapted for medical use; dietetic foods for the prevention and treatment of prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; dietetic foods for the treatment and prevention of obesity and being overweight; dietetic foods for the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol, LDL cholesterol levels and blood lipids; dietetic preparations adapted for medical use; dietetic substances in the nature of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions adapted for medical use; dietetic preparations and substances for glycemic control; dietetic preparations and substances for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; dietary and nutritional supplements for glycemic control; health food supplements for persons with special dietary requirements; pharmaceuticals and natural remedy preparations for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; preparations for use in naturopathy for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; chemical preparations for medical purposes for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; pharmaceutical preparations and chemico- pharmaceutical preparations for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; chemical preparations for pharmaceutical purposes for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; pharmaceutical preparations and substances for glycemic control; pharmaceutical preparations and substances for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; pharmaceutical preparations in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions for use in glycemic control; pharmaceutical preparations in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions for use in the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; pharmaceutical preparations and substances and dietary and nutritional substances in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions, all for use in the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol and LDL cholesterol levels, liver disease, steatohepatitis, infantile colic, gut microbiota, insulin levels and resistance, blood lipids, diarrhea, constipation, colitis; pharmaceutical preparations and substances and dietary and nutritional substances in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions, all for use in the treatment and regulation of intestinal injury or inflammation, Crohn's disease, cardiovascular risk factors, post bariatric surgery patients, and not including products primarily for use in the treatment of angina pectoris and high blood pressure
  • Class 010 — Medical apparatus: Surgical and medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; capsulated medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; medical devices for the treatment and prevention of obesity and being overweight, and for use in weight control; medical devices for the treatment and prevention of prediabetes, diabetes and glycemic control, and for the improvement of overall metabolic health; medical devices for use in the prevention and treatment of prediabetes and diabetes; orally administered medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; surgical and medical devices, capsulated devices and orally administered medical devices all for use in the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol and LDL cholesterol levels, liver disease, steatohepatitis, infantile colic, gut microbiota, insulin levels and resistance, blood lipids, diarrhea, constipation, intestinal injury or inflammation, colitis, Crohn's disease, cardiovascular risk factors, post bariatric surgery patients

Owner

Prosecution history

  • 14 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 14 Jan 2026 — SOU EXTENSION 2 GRANTED
  • 13 Jan 2026 — SOU EXTENSION 2 FILED
  • 13 Jan 2026 — SOU TEAS EXTENSION RECEIVED
  • 02 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 01 Jul 2025 — SOU EXTENSION 1 GRANTED
  • 01 Jul 2025 — SOU EXTENSION 1 FILED
  • 01 Jul 2025 — SOU TEAS EXTENSION RECEIVED
  • 14 Jan 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 03 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 03 Dec 2024 — PUBLISHED FOR OPPOSITION
  • 27 Nov 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 09 Nov 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 08 Nov 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 08 Nov 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE

View this trademark record on Marksy